Indeed, in our studies, we observed that patient-derived RCC myeloid cells have the ability to suppress T-cell function, and in Renca models, tumors of PBS- and IgG control-treated RCC mice, a large proportion of macrophages exhibited an M2 phenotype characterized by CD206+ expression. This evidence concerns the gene MRC1 and renal cell carcinoma.